Immunome director buys 2,000 common shares

Immunome Inc. director Jean Jacques Bienaimé reported open-market purchases of the company’s common stock.

(Moderate)

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Immunome Inc. director Jean Jacques Bienaimé reported open-market purchases of the company’s common stock. On March 10, 2026, he bought 1,000 shares at $22.12 per share, followed by another 1,000 shares at $21.55 per share on March 11, 2026. After these total purchases of 2,000 shares, he directly owns 38,415 shares of Immunome common stock.

Insider Trade Summary

Net Buyer: 2,000 shares

Net Buy 2 txns

Insider BIENAIME JEAN JACQUES

Role Director

Bought 2,000 shs ($44K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,000	$21.55	$22K
Purchase	Common Stock	1,000	$22.12	$22K

Holdings After Transaction: Common Stock — 38,415 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Immunome (IMNM) disclose in this Form 4?

Immunome disclosed that director Jean Jacques Bienaimé made two open-market purchases of common stock totaling 2,000 shares. He bought 1,000 shares on March 10, 2026, and another 1,000 shares on March 11, 2026, at prices just above $21 per share.

How many Immunome (IMNM) shares did the director buy and at what prices?

The director bought a total of 2,000 Immunome common shares in two transactions. He purchased 1,000 shares at $22.12 per share on March 10, 2026, and 1,000 shares at $21.55 per share on March 11, 2026, in open-market trades.

What is Jean Jacques Bienaimé’s Immunome (IMNM) shareholding after these transactions?

Following the reported transactions, Jean Jacques Bienaimé directly holds 38,415 shares of Immunome common stock. This figure reflects his position after buying 1,000 shares on March 10, 2026, and another 1,000 shares on March 11, 2026, in open-market purchases.

Were the Immunome (IMNM) insider transactions open-market purchases or another type?

Both transactions were open-market purchases of Immunome common stock. The Form 4 classifies them with transaction code “P,” described as a purchase in an open market or private transaction, covering 1,000 shares on each of March 10 and March 11, 2026.

Did the Immunome (IMNM) Form 4 report any stock sales or derivative exercises?

The Form 4 reports only purchases of Immunome common stock and no sales. It shows two non-derivative transactions coded as open-market purchases totaling 2,000 shares, with no derivative exercises, tax withholdings, gifts, or restructuring transactions listed in the summary data.

Who is the reporting person in the Immunome (IMNM) Form 4 and what is their role?

The reporting person is Jean Jacques Bienaimé, identified as a director of Immunome Inc. He is not listed as an officer or a ten percent owner in this filing. The reported transactions reflect his direct ownership of Immunome common stock after the purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/12/2026 - 06:05 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last)

(First)

(Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL

98011

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/10/2026		P		1,000	A	$22.12	37,415	D
Common Stock	03/11/2026		P		1,000	A	$21.55	38,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Sandra Stoneman, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR